BUYINS.NET: Market Maker Surveillance Report. Top 6 Highest Net Buy Volume With Lowest Price Friction Stocks For January 29, 2009

Jan 30, 2009 (M2 PRESSWIRE via COMTEX) -- SYMC | Quote | Chart | News | PowerRating -- BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for January 29, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This "fair market making" requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3,039 companies with "abnormal" market making, 1,407 companies with positive Friction Factors and 4,483 companies with negative Friction Factors. Here is a list of the top 6 companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Symantec Corporation (NASDAQ: SYMC), Merck & Co. (NYSE: MRK), Baxter International (NYSE: BAX), NovaGold Resources (AMEX: NG), Silver Wheaton Corp (NYSE: SLW | Quote | Chart | News | PowerRating) and Sepracor (NASDAQ: SEPR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net.

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

SYMC $0.83 5.67% 14,202,130 51.94% 12,909,987 47.22% 1,292,143 15,568

MRK $0.16 0.56% 5,389,506 44.89% 4,247,898 35.38% 1,141,608 71,351

BAX $0.08 0.14% 2,423,022 48.33% 1,281,515 25.56% 1,141,507 142,688

NG $0.52 17.75% 4,429,679 48.39% 3,500,180 38.24% 929,499 17,875

SLW $0.20 3.12% 4,279,644 46.43% 3,431,741 37.23% 847,903 42,395

SEPR $2.24 16.43% 6,838,245 51.89% 6,054,028 45.94% 784,217 3,501

Click here to view chart: http://www.buyins.com/ff/ffnvup1-29-09.jpg

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume - sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows SYMC with a Net Buy Volume of 1,292,143 shares and a Friction Factor of 15,568 shares. That means that it takes 15,568 more shares of buying than selling to move SYMC higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Thursday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

Symantec Corporation (NASDAQ: SYMC | Quote | Chart | News | PowerRating) provides software and services that protect, manage, and control information risks related to security, data protection, storage, compliance, and systems management. The company operates in four segments: Consumer Products, Security and Compliance, Storage and Server Management, and Services. The Consumer Products segment focuses on delivering the companys Internet security, personal computer (PC) tuneup, and backup products to individual users and home offices. The Security and Compliance segment provides solutions for compliance and security management, endpoint security, messaging management, and data protection management software solutions that enable businesses to secure, provide, backup, and remotely access their laptops, PCs, mobile devices, and servers. The Storage and Server Management segment offers storage and server management, data protection, and application performance management solutions across heterogeneous storage and server platforms to enterprises. The Services segment provides information technology risk management services and solutions to manage security, availability, performance, and compliance risks across multi-vendor environments. It also offers managed security services, consulting, education, and threat and early warning systems. The company offers its services to enterprises, governments, small and medium-sized businesses, and consumers worldwide. Symantec Corporation was founded in 1982 and is headquartered in Cupertino, California.

Merck & Co., Inc. (NYSE: MRK | Quote | Chart | News | PowerRating) provides products for human and animal health in the United States and internationally. The companys Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Zocor, an atherosclerosis product; Cosopt and Trusopt, the ophthalmological products; Primaxin and Cancidas, the anti bacterial/anti fungal products; Januvia and Janumet for type 2 diabetes; Maxalt, an acute migraine product; Proscar to treat symptomatic benign prostate enlargement; Propecia for the treatment of male pattern hair loss; Arcoxia to treat arthritis and pain; Crixivan and Stocrin for the treatment of HIV infection; Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting; and Invanz for treating infection. Merck & Co.s Vaccines segment comprises human health vaccine products, such as preventative pediatric, adolescent, and adult vaccines administered at physician offices. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; RotaTeq to protect against rotavirus gastroenteritis in infants and children; Zostavax for preventing shingles; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; and M-M-R II, a vaccine against measles, mumps, and rubella. Merck & Co. has agreements with Neuromed Pharmaceuticals, Ltd., FoxHollow Technologies, Inc., Ariad Pharmaceuticals, Inc., and GTX, Inc, as well as collaborations with Metabasis Therapeutics, Inc. Idera Pharmaceuticals, Inc., and Karo Bio AB. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Baxter International, Inc. (NYSE: BAX | Quote | Chart | News | PowerRating) operates as a healthcare company worldwide. It offers medical devices, pharmaceuticals, and biotechnology products for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. The BioScience segment manufactures recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as proteins used in hemostasis, wound-sealing, and tissue regeneration; and vaccines. The Medication Delivery segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to drug formulation and packaging technologies. The Renal segment provides products to treat end-stage renal disease, or irreversible kidney failure. It also manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy; and distributes products for hemodialysis (HD), which is conducted in a hospital or clinic. It markets its products through independent distributors, drug wholesalers, specialty pharmacy, and homecare companies to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and by patients at home under physician supervision. The company has a collaboration agreement with HHD, LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. to develop a home HD machine. Baxter International was founded in 1931 and is based in Deerfield, Illinois.

NovaGold Resources, Inc. (AMEX: NG), through its subsidiaries, engages in the exploration and development of gold and copper properties in Alaska and British Columbia. The company owns interest in the Donlin Creek gold project in southwestern Alaska; a 50% interest in the Galore Creek copper-gold-silver project in British Columbia; and a 100% interest in the Grace claims located in northwestern British Columbia. It also owns a 100% interest in the Nome Gold property, which comprises Rock Creek, Big Hurrah, and Nome Gold projects located near the town of Nome, Alaska. In addition, NovaGold Resources has an option to acquire a 51% joint venture interest in the Ambler property with copper, zinc, gold, silver, and lead deposits located in northern Alaska. Further, the company operates hydroelectric projects located in British Columbia; and engages in the sale of sand, gravel, and land. The company was founded in 1984. It was formerly known as NovaCan Mining Resources (l985) Limited and changed its name to NovaGold Resources, Inc. in 1987. NovaGold Resources is based in Vancouver, Canada.

Silver Wheaton Corp. (NYSE: SLW), a mining company, engages in the silver production. The company purchases silver from Goldcorp mines in Mexico, Zinkgruvan Mine in Sweden, Yauliyacu Mine in Peru, and Stratoni Mine in Greece. Silver Wheaton Corp. was incorporated in 1994. It was formerly known as Chap Mercantile, Inc. and changed name to Silver Wheaton Corp. in 2004. The company is headquartered in Vancouver, Canada.

Sepracor, Inc. (NASDAQ: SEPR | Quote | Chart | News | PowerRating) engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. It develops products for the synthesis and separation of pharmaceutical and biopharmaceutical compounds. The company markets XOPENEX (levalbuterol HCl) Inhalation Solution for the treatment of bronchospasm in the lung; XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol for the treatment of bronchospasm; and LUNESTA (eszopiclone) for the treatment of insomnia. It also offers BROVANA (arformoterol tartrate) Inhalation Solution, a long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Sepracors out-licensing agreements include Schering-Plough for CLARINEX (desloratadine); sanofi-aventis for ALLEGRA (fexofenadine HCl); and UCB S.A. for XYZAL/XUSALTM (levocetirizine). The companys product pipeline comprises SEP-225289, under Phase I studies, for the treatment of major depressive disorder (MDD); SEP-227162, a serotonin and norepinephrine reuptake inhibitor for the treatment of depression and anxiety, is under Phase I clinical study; SEP-225441, a GABAA agonist and potent anxiolytic in preclinical models; SEP-225432 and SEP-225425 for the treatment of MDD; and SEP-0002093. Sepracor offers its products primary to care physicians, allergists, pulmonologists, pediatricians, hospitals, psychiatrists, and sleep specialists through its sales professionals. It has an agreement with Eisai Co., Ltd. for the development and commercialization of its eszopiclone product, LUNESTA in Japan. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,400,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index